WO2009087682A3 - Nouvelle formulation de prégabaline injectable stabilisée - Google Patents
Nouvelle formulation de prégabaline injectable stabilisée Download PDFInfo
- Publication number
- WO2009087682A3 WO2009087682A3 PCT/IN2008/000869 IN2008000869W WO2009087682A3 WO 2009087682 A3 WO2009087682 A3 WO 2009087682A3 IN 2008000869 W IN2008000869 W IN 2008000869W WO 2009087682 A3 WO2009087682 A3 WO 2009087682A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pregabalin
- injectable formulation
- formulation
- injectable
- stabilized injectable
- Prior art date
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title abstract 5
- 229960001233 pregabalin Drugs 0.000 title abstract 5
- 239000007972 injectable composition Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention porte sur une formulation injectable de prégabaline stable, de pH située entre 4,0 et 8,0. En outre, la présente invention porte sur un procédé de fabrication de la formulation de prégabaline injectable. La formulation de prégabaline injectable proposée par la présente invention est administrée par voie intraveineuse à des patients nécessitant un traitement à la prégabaline.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08869815A EP2240158A2 (fr) | 2007-12-28 | 2008-12-26 | Formulation de prégabaline injectable stabilisée |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2596/MUM/2007 | 2007-12-28 | ||
IN2596MU2007 | 2007-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009087682A2 WO2009087682A2 (fr) | 2009-07-16 |
WO2009087682A3 true WO2009087682A3 (fr) | 2009-09-11 |
Family
ID=40801860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2008/000869 WO2009087682A2 (fr) | 2007-12-28 | 2008-12-26 | Nouvelle formulation de prégabaline injectable stabilisée |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2240158A2 (fr) |
WO (1) | WO2009087682A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7500600B2 (ja) | 2019-03-26 | 2024-06-17 | オリオン コーポレーション | プレガバリン製剤およびその使用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109498611B (zh) * | 2019-01-15 | 2020-09-01 | 张惊宇 | 一种治疗糖尿病周围神经痛的药物及其用途 |
CN112353767A (zh) * | 2020-11-16 | 2021-02-12 | 海南锦瑞制药有限公司 | 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用 |
CN113069411B (zh) * | 2021-04-02 | 2022-08-09 | 石家庄四药有限公司 | 一种己酮可可碱注射液及其制备方法 |
WO2022256545A1 (fr) * | 2021-06-04 | 2022-12-08 | Nevakar Injectables Inc. | Formulations de prégabaline injectables |
GB2624861A (en) | 2022-11-28 | 2024-06-05 | Orbit Pharma Ltd | Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058641A1 (fr) * | 1997-06-25 | 1998-12-30 | Warner-Lambert Company | Utilisation d'analogues de gaba, telle la gabapentine, dans la fabrication d'un medicament servant a traiter des maladies inflammatoires |
WO2000061135A1 (fr) * | 1999-04-08 | 2000-10-19 | Warner-Lambert Company | Methode de traitement pour l'incontinence |
WO2003061656A1 (fr) * | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals Inc. | Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central |
US20050090550A1 (en) * | 2003-09-11 | 2005-04-28 | Barrett Ronald W. | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs |
US20060229361A1 (en) * | 2005-04-06 | 2006-10-12 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US20060281816A1 (en) * | 2005-04-11 | 2006-12-14 | Lilach Hedvati | Pregabalin free of lactam and a process for preparation thereof |
EP1992609A1 (fr) * | 2007-05-14 | 2008-11-19 | Dipharma Francis S.r.l. | Processus de préparation d'acide (S)(+)-3-(aminomethyl)-5-methylhexanoique |
-
2008
- 2008-12-26 WO PCT/IN2008/000869 patent/WO2009087682A2/fr active Application Filing
- 2008-12-26 EP EP08869815A patent/EP2240158A2/fr not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058641A1 (fr) * | 1997-06-25 | 1998-12-30 | Warner-Lambert Company | Utilisation d'analogues de gaba, telle la gabapentine, dans la fabrication d'un medicament servant a traiter des maladies inflammatoires |
WO2000061135A1 (fr) * | 1999-04-08 | 2000-10-19 | Warner-Lambert Company | Methode de traitement pour l'incontinence |
WO2003061656A1 (fr) * | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals Inc. | Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central |
US20050090550A1 (en) * | 2003-09-11 | 2005-04-28 | Barrett Ronald W. | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs |
US20060229361A1 (en) * | 2005-04-06 | 2006-10-12 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US20060281816A1 (en) * | 2005-04-11 | 2006-12-14 | Lilach Hedvati | Pregabalin free of lactam and a process for preparation thereof |
EP1992609A1 (fr) * | 2007-05-14 | 2008-11-19 | Dipharma Francis S.r.l. | Processus de préparation d'acide (S)(+)-3-(aminomethyl)-5-methylhexanoique |
Non-Patent Citations (1)
Title |
---|
SHI W ET AL: "DESIGN, SYNTHESIS, AND PRELIMINARY EVALUATION OF GABAPENTIN-PREGABALIN MUTUAL PRODRUGS IN RELIEVING NEUROPATHIC PAIN", ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 338, no. 8, 1 January 2005 (2005-01-01), pages 358 - 364, XP008067446, ISSN: 0365-6233 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7500600B2 (ja) | 2019-03-26 | 2024-06-17 | オリオン コーポレーション | プレガバリン製剤およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
WO2009087682A2 (fr) | 2009-07-16 |
EP2240158A2 (fr) | 2010-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009012163A (es) | Hetarilanilinas como moduladores para beta-amiloide. | |
MX2008014101A (es) | Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos. | |
WO2007106469A3 (fr) | Derives bicycliques de l'acide carboxylique utiles dans le traitement de troubles metaboliques | |
WO2006099941A8 (fr) | 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments | |
NZ596187A (en) | Use of an anti-tau ps422 antibody for the treatment of brain diseases | |
WO2009087682A3 (fr) | Nouvelle formulation de prégabaline injectable stabilisée | |
WO2006058648A3 (fr) | Acides biaryloxymethylarenecarboxyliques | |
WO2011127333A3 (fr) | Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques | |
WO2008033562A3 (fr) | Composés inhibiteurs de kinases | |
WO2007136759A3 (fr) | Procédé de traitement et de prévention de troubles oculaires | |
WO2007115620A3 (fr) | Nouveaux composés de cyclobutyle en tant qu'inhibiteurs de kinase | |
WO2006078463A3 (fr) | Methode de traitement de maladie cardio-vasculaire | |
WO2007133673A3 (fr) | Procédés de traitement d'un trouble neurologique avec du monohydrate de créatine | |
WO2007133731A3 (fr) | Composés de ligand de créatine et procédés d'utilisation correspondants | |
WO2011023367A3 (fr) | Promédicaments bisphosphonates | |
WO2007010281A3 (fr) | Utilisation de derives et d'analogues de thiazole dans les troubles causes par les acides gras libres | |
TNSN07452A1 (en) | Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine | |
WO2009074247A8 (fr) | Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament | |
WO2007056236A3 (fr) | Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides administree par voie intraveineuse | |
WO2007104485A3 (fr) | Composés imidazo[2,1-b]thiazole substitués et utilisation dans la fabrication de médicaments | |
WO2008081268A3 (fr) | Compositions pharmaceutiques d'entacapone | |
WO2007095021A3 (fr) | Nouveaux composés | |
WO2008118792A3 (fr) | Lymphocytes t gamma delta et procédés de traitement de problèmes liés à l'interleukine-17 | |
WO2008059041A3 (fr) | Complémentation d'un déficit de facteur xi par mutants de facteur v | |
WO2008023003A8 (fr) | Associations médicamenteuses destinées au traitement de maladies des voies respiratoires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08869815 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008869815 Country of ref document: EP |